ArticlePhysiological research2026
Hypoxia-Inducible Factor-1alpha/BNIP3-Mediated Mitochondrial Autophagy in Septic Cardiomyopathy: Protective Mechanism for Cardiac Function.
Article in Physiological research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to examine the role of hypoxia-inducible factor-1alpha (HIF-1alpha) in septic cardiomyopathy (SCM), focusing on its regulatory function in mitochondrial autophagy. Differentially expressed genes (DEGs) associated with SCM were identified through analysis of the GSE79962 dataset. Mitochondrial autophagy-related genes were retrieved from the GeneCards database. Genes common to both datasets were identified using Venn diagram analysis, followed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses. A murine model of SCM was established via intraperitoneal injection of lipopolysaccharide (LPS). Mice were subsequently treated with either dimethyloxalylglycine (DMOG) a HIF-1alpha stabilizer, or 3-methyladenine (3-MA), an inhibitor of mitochondrial autophagy. Cardiac function, myocardial injury, inflammatory response, mitochondrial integrity, and expression levels of HIF-1alpha and mitochondrial autophagy markers were assessed using echocardiography, enzyme-linked immunosorbent assay (ELISA), hematoxylin-eosin staining, immunofluorescence, transmission electron microscopy, and western blot analysis. KEGG pathway analysis indicated significant enrichment of the overlapping genes in the HIF-1 signaling pathway. In vivo, DMOG administration stabilized HIF-1alpha expression and upregulated Bcl-2-interacting protein 3 (BNIP3), thereby enhancing mitochondrial autophagy. This enhancement was associated with reduced myocardial enzyme release and inflammatory cytokine production, as well as improvements in mitochondrial ultrastructure, myocardial histopathology, and cardiac function. In contrast, 3-MA inhibited mitochondrial autophagy and attenuated the myocardial protective effects associated with HIF-1alpha stabilization. Activation of the HIF-1alpha/BNIP3 signaling axis promotes mitochondrial autophagy and confers protective on cardiac function in septic cardiomyopathy. These findings present a potential mechanistic pathway and therapeutic target for mitigating myocardial injury associated with septic cardiomyopathy.
Indexed as
Identifiers
42187507PMC13225450What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.